About Guanine nucleotide-binding protein G(i) subunit alpha-1
Guanine nucleotide-binding protein G(i) subunit alpha-1 (GNAI1) is a protein
from Homo sapiens identified by UniProt accession
P63096, 354 residues long.
MolForge cross-references it against 0 known binders and
230 disease associations.
Target properties
| Protein name | Guanine nucleotide-binding protein G(i) subunit alpha-1 |
| UniProt accession | P63096 |
| Gene | GNAI1 |
| Organism | Homo sapiens |
| Length | 354 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (230)
Diseases linked to this target (Open Targets).
- complex neurodevelopmental disorder · score 0.37
- PHF-tau measurement · score 0.33
- neurodegenerative disease · score 0.32
- protein measurement · score 0.31
- Neurodevelopmental disorder · score 0.31
- Seizure · score 0.27
- Neurodevelopmental abnormality · score 0.26
- nicotine dependence · score 0.26
- triglyceride measurement · score 0.25
- sleep duration · score 0.25
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P63096-F1 | alphafold | PREDICTED | 93.73 | — |
Amino-acid sequence (354 residues)
MGCTLSAEDK AAVERSKMID RNLREDGEKA AREVKLLLLG AGESGKSTIV KQMKIIHEAG YSEEECKQYK AVVYSNTIQS IIAIIRAMGR LKIDFGDSAR ADDARQLFVL AGAAEEGFMT AELAGVIKRL WKDSGVQACF NRSREYQLND SAAYYLNDLD RIAQPNYIPT QQDVLRTRVK TTGIVETHFT FKDLHFKMFD VGGQRSERKK WIHCFEGVTA IIFCVALSDY DLVLAEDEEM NRMHESMKLF DSICNNKWFT DTSIILFLNK KDLFEEKIKK SPLTICYPEY AGSNTYEEAA AYIQCQFEDL NKRKDTKEIY THFTCATDTK NVQFVFDAVT DVIIKNNLKD CGLF
Explore Guanine nucleotide-binding protein G(i) subunit alpha-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets